Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
Department of Pathology, Beifang Hospital of China Medical University, General Hospital of Northern Theater Command, Shenyang, Liaoning 110004, P.R. China.
Int J Mol Med. 2025 Jan;55(1). doi: 10.3892/ijmm.2024.5446. Epub 2024 Oct 25.
A dynamic balance exists between osteogenesis and osteoclastogenesis in bone tissue, which can lead to several bone diseases, such as osteoporosis, osteoarthritis, bone necrosis and bone defects, in cases of insufficient osteogenesis or excessive osteoclastogenesis. NEL‑like molecule‑1 (NELL‑1) was first discovered in 1999 as an osteogenic factor that can prevent or treat bone diseases by increasing osteogenic levels. To date, research has identified multiple signaling pathways involved in improving osteogenic levels. Furthermore, to apply NELL‑1 in clinical practice, researchers have optimized its osteogenic effect by combining it with other molecules, changing its molecular structure and performing bone tissue engineering. Currently, research on NELL‑1 is gaining increasing attention. In the near future, it will definitely be applied in clinical practice to eliminate diseases. Thus, the present study provides a comprehensive review of NELL‑1 in enhancing osteogenic levels from the perspectives of the molecular mechanism, interactions with other molecules/cells, molecular‑level changes, applications in bone tissue engineering and its expression in tumors, providing a solid theoretical basis for its clinical application.
在骨组织中，成骨作用和破骨细胞形成之间存在动态平衡，在成骨作用不足或破骨细胞形成过度的情况下，可能会导致几种骨病，如骨质疏松症、骨关节炎、骨坏死和骨缺损。NEL-样分子-1（NELL-1）于 1999 年首次被发现，作为一种成骨因子，通过增加成骨水平来预防或治疗骨病。迄今为止，研究已经确定了多个涉及提高成骨水平的信号通路。此外，为了将 NELL-1 应用于临床实践，研究人员通过将其与其他分子结合、改变其分子结构和进行骨组织工程来优化其成骨作用。目前，对 NELL-1 的研究受到越来越多的关注。在不久的将来，它肯定会在临床上得到应用，以消除疾病。因此，本研究从分子机制、与其他分子/细胞的相互作用、分子水平变化、在骨组织工程中的应用及其在肿瘤中的表达等方面，对 NELL-1 增强成骨水平进行了全面综述，为其临床应用提供了坚实的理论基础。
